472 related articles for article (PubMed ID: 24886434)
21. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer.
Wen W; Liang W; Wu J; Kowolik CM; Buettner R; Scuto A; Hsieh MY; Hong H; Brown CE; Forman SJ; Horne D; Morgan R; Wakabayashi M; Dellinger TH; Han ES; Yim JH; Jove R
Mol Cancer Ther; 2014 Dec; 13(12):3037-48. PubMed ID: 25319391
[TBL] [Abstract][Full Text] [Related]
22. Curcumin suppresses stem-like traits of lung cancer cells via inhibiting the JAK2/STAT3 signaling pathway.
Wu L; Guo L; Liang Y; Liu X; Jiang L; Wang L
Oncol Rep; 2015 Dec; 34(6):3311-7. PubMed ID: 26397387
[TBL] [Abstract][Full Text] [Related]
23. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells.
Zhang R; Chen X; Fu S; Xu L; Lin J
Oncol Rep; 2020 Sep; 44(3):1224-1232. PubMed ID: 32705214
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological targeting PTK6 inhibits the JAK2/STAT3 sustained stemness and reverses chemoresistance of colorectal cancer.
Liu C; Pan Z; Chen Q; Chen Z; Liu W; Wu L; Jiang M; Lin W; Zhang Y; Lin W; Zhou R; Zhao L
J Exp Clin Cancer Res; 2021 Sep; 40(1):297. PubMed ID: 34551797
[TBL] [Abstract][Full Text] [Related]
25. Investigation of ovatodiolide, a macrocyclic diterpenoid, as a potential inhibitor of oral cancer stem-like cells properties via the inhibition of the JAK2/STAT3/JARID1B signal circuit.
Lin CS; Bamodu OA; Kuo KT; Huang CM; Liu SC; Wang CH; Tzeng YM; Chao TY; Yeh CT
Phytomedicine; 2018 Jul; 46():93-103. PubMed ID: 30097127
[TBL] [Abstract][Full Text] [Related]
26. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
27. Pterostilbene suppresses gastric cancer proliferation and metastasis by inhibiting oncogenic JAK2/STAT3 signaling: In vitro and in vivo therapeutic intervention.
He P; Li Y; Hu J; Deng B; Tan Z; Chen Y; Yu B; Dong W
Phytomedicine; 2024 Jun; 128():155316. PubMed ID: 38518635
[TBL] [Abstract][Full Text] [Related]
28. Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden.
Li H; Qian Y; Wang X; Pi R; Zhao X; Wei X
Cell Prolif; 2020 Jan; 53(1):e12719. PubMed ID: 31778258
[TBL] [Abstract][Full Text] [Related]
29. The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.
Baskin R; Park SO; Keserű GM; Bisht KS; Wamsley HL; Sayeski PP
PLoS One; 2014; 9(8):e105568. PubMed ID: 25162558
[TBL] [Abstract][Full Text] [Related]
30. Zerumbone inhibits growth of hormone refractory prostate cancer cells by inhibiting JAK2/STAT3 pathway and increases paclitaxel sensitivity.
Jorvig JE; Chakraborty A
Anticancer Drugs; 2015 Feb; 26(2):160-6. PubMed ID: 25243457
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-503-5p Inhibits the CD97-Mediated JAK2/STAT3 Pathway in Metastatic or Paclitaxel-Resistant Ovarian Cancer Cells.
Park GB; Kim D
Neoplasia; 2019 Feb; 21(2):206-215. PubMed ID: 30622051
[TBL] [Abstract][Full Text] [Related]
32. ZnAs@SiO
Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
[No Abstract] [Full Text] [Related]
33. B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation.
Liu H; Tekle C; Chen YW; Kristian A; Zhao Y; Zhou M; Liu Z; Ding Y; Wang B; Mælandsmo GM; Nesland JM; Fodstad O; Tan M
Mol Cancer Ther; 2011 Jun; 10(6):960-71. PubMed ID: 21518725
[TBL] [Abstract][Full Text] [Related]
34. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
35. CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway.
Wang L; Zhang F; Cui JY; Chen L; Chen YT; Liu BW
Oncol Rep; 2018 May; 39(5):2081-2090. PubMed ID: 29565447
[TBL] [Abstract][Full Text] [Related]
36. Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429.
Guo Q; Lu L; Liao Y; Wang X; Zhang Y; Liu Y; Huang S; Sun H; Li Z; Zhao L
Cell Death Dis; 2018 Jan; 8(1):e3178. PubMed ID: 29324735
[TBL] [Abstract][Full Text] [Related]
37. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
[TBL] [Abstract][Full Text] [Related]
38. Acylglycerol kinase promotes paclitaxel resistance in nasopharyngeal carcinoma cells by regulating FOXM1 via the JAK2/STAT3 pathway.
Zhao C; Chen HY; Zhao F; Feng HJ; Su JP
Cytokine; 2021 Dec; 148():155595. PubMed ID: 34116927
[TBL] [Abstract][Full Text] [Related]
39. Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.
Gritsina G; Xiao F; O'Brien SW; Gabbasov R; Maglaty MA; Xu RH; Thapa RJ; Zhou Y; Nicolas E; Litwin S; Balachandran S; Sigal LJ; Huszar D; Connolly DC
Mol Cancer Ther; 2015 Apr; 14(4):1035-47. PubMed ID: 25646015
[TBL] [Abstract][Full Text] [Related]
40. S-adenosylmethionine induces apoptosis and cycle arrest of gallbladder carcinoma cells by suppression of JAK2/STAT3 pathways.
Liu Y; Bi T; Yuan F; Gao X; Jia G; Tian Z
Naunyn Schmiedebergs Arch Pharmacol; 2020 Dec; 393(12):2507-2515. PubMed ID: 32219484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]